Bristol-Meyers Squibb to Halt Sales of Serzone in U.S.
May 20, 2004
Bristol-Myers Squibb will stop selling
its controversial antidepressant Serzone in the United States
starting next month, a company spokesman said. Serzone has
been linked to dozens of cases of liver failure and injury,
including at least 20 deaths.
The drug, the subject of several
lawsuits, is one of 17 to be discontinued due to poor sales and
growing competition, said Robert Hutchinson, a spokesman for
Bristol-Myers.
Click here to read about the most trusted and tested St. John's Wort formulation in America.
Click here to read about other natural antidepressant/emotional mood balancers
